Skip to content

Abstract 14486: Comparative Cardiovascular and Mortality Outcomes of GLP-1 Receptor Agonists versus SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Propensity Score-Matched Cohort Study

Nov 2026 · Circulation · Vol 154 · 0 citations

TL;DR

GLP-1 RA therapy was associated with significantly lower risks of major adverse cardiovascular outcomes and all-cause mortality compared with SGLT2 inhibitors, suggesting a potential advantage of GLP-1 RA therapy for long-term cardiovascular risk reduction in patients with T2DM.

Abstract

Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) are widely used in the management of type 2 diabetes mellitus (T2DM) and have demonstrated cardiovascular benefits. However, real-world comparative data evaluating major cardiovascular outcomes and mortality between these therapeutic classes remain limited. We compared cardiovascular and mortality outcomes among patients with T2DM receiving GLP-1 RAs versus SGLT2 inhibitors. Methods: We conducted a retrospective cohort study using the TriNetX Research Network. Adult patients with T2DM receiving GLP-1 RAs without SGLT2 inhibitors were compared with patients receiving SGLT2 inhibitors without GLP-1 RAs. After propensity score matching, 419,760 patients were included in each cohort. Outcomes assessed from 1 day after treatment initiation included myocardial infarction (MI), atherosclerosis, cerebral infarction, heart failure (HF), and all-cause mortality. Risk ratios (RRs) and hazard ratios (HRs) were calculated. Results: Following matching, GLP-1 RA therapy was associated with significantly lower risks of all evaluated outcomes compared with SGLT2 inhibitors. Patients receiving GLP-1 RAs had lower risks of MI (4.1% vs 7.8%; RR 0.52, HR 0.49), atherosclerosis (6.7% vs 7.9%; RR 0.84, HR 0.80), cerebral infarction (4.8% vs 6.3%; RR 0.77, HR 0.73), HF (12.2% vs 25.0%; RR 0.49, HR 0.43), and all-cause mortality (6.0% vs 7.3%; RR 0.82, HR 0.77) (all p<0.001). Conclusions: In this large propensity score-matched real-world cohort of patients with T2DM, GLP-1 receptor agonists were associated with significantly lower risks of major adverse cardiovascular outcomes and all-cause mortality compared with SGLT2 inhibitors. These findings suggest a potential advantage of GLP-1 RA therapy for long-term cardiovascular risk reduction in patients with T2DM.

View source

Similar papers

Nov 2026

Abstract 14492: Comparative Cardiovascular Outcomes of SGLT2 Inhibitors versus DPP-4 Inhibitors in Patients with Type 2 Diabetes: A Propensity Score-Matched Real-World Analysis

Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and dipeptidyl peptidase-4 inhibitors (DPP4i) are commonly used second-line agents in type 2 diabetes mellitus (T2DM). This large-scale real-world analysis compared their effects on major cardiovascular, renal, and diabetes-related complications. Me...

Sajjad Ahmed Khan, Anurag Marasini · 0 citations
Nov 2026

Abstract 16799: Comparative Cardiovascular Outcomes of GLP-1 Receptor Agonists versus SGLT2 Inhibitors in Patients with Prior Myocardial Infarction and Overweight or Obesity: A Propensity-Matched Analysis

In patients with prior MI and overweight or obesity, GLP-1 RA use was associated with substantially lower risk of MACE and new-onset heart failure than SGLT2i, with consistent benefit across ischemic and pulmonary vascular outcomes and neutral effects on mortality.

Zaid Al-Kofahi, H. Alhammouri, F. Qtaishat et al. · 0 citations
Nov 2026

Abstract 14482: Comparative Cardiovascular Outcomes of GLP-1 Receptor Agonists versus DPP-4 Inhibitors in Patients with Type 2 Diabetes: A Propensity Score-Matched Real-World Analysis

Background: Glucagon-like peptide-1 receptor agonists (GLP1RA) and dipeptidyl peptidase-4 inhibitors (DPP4i) are commonly used second-line agents in type 2 diabetes mellitus (T2DM). This large-scale real-world analysis compared their effects on major clinical outcomes. Methods: Using the TriNetX Research netwo...

Sajjad Ahmed Khan, Anurag Marasini · 0 citations
Nov 2026

Abstract 14707: Synergistic Cardiovascular Benefits of Combined GLP-1 Receptor Agonists and SGLT2 Inhibitors versus SGLT2 Inhibitor Monotherapy in Patients with Type 2 Diabetes and HFpEF

Background: Both glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) provide cardiovascular benefits in type 2 diabetes (T2D). While SGLT2i is a cornerstone therapy for heart failure with preserved ejection fraction (HFpEF), the incremental prognostic benefit of...

A. Bielecka-Dąbrowa, M. Banach, Akash Jaiswal et al. · 0 citations
Nov 2026

Abstract 8980: Incremental Kidney and Glycemic Outcomes Associated with GLP-1 Receptor Agonist Plus SGLT2 Inhibitor Therapy versus SGLT2 Inhibitor Monotherapy in Adults with Type 2 Diabetes, Heart Failure and Chronic Kidney Disease

Background: Patients with type 2 diabetes mellitus (T2DM), heart failure (HF), and chronic kidney disease (CKD) remain at high risk for renal deterioration, glycaemic emergencies, and adverse cardiovascular outcomes despite contemporary therapy. Although sodium-glucose cotransporter-2 inhibitors (SGLT2i) improve car...

Emmanuel Adjei-Wiafe, G. Blankson, E. Ansah et al. · 0 citations
Nov 2026

Abstract 15267: Efficacy and Safety of Combination Therapy with GLP-1 and SGLT2 Inhibitors versus GLP-1 Monotherapy in Patients with Type 2 Diabetes and Heart Failure with Preserved Ejection Fraction (HFpEF)

Background: According to the European Society of Cardiology (ESC) guidelines, both GLP-1 receptor agonists and SGLT2 inhibitors have documented cardiovascular benefits in patients with type 2 diabetes mellitus (T2DM), with SGLT2 inhibitors particularly recommended to reduce heart failure hospitalizations. However, r...

Vikash Jaiswal, M. Banach, Akash Jaiswal et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.